Global Autoimmune Partnering 2014-2021: Deal trends, players and financials

$3,495.00

The Global Autoimmune Partnering 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies

Publication date
April 2021
Number of pages
700+
Product type
Research report
Available formats
PDF document
Report edition
2
SKU
CP2228

Global Autoimmune Partnering 2014 to 2021 provides the full collection of Autoimmune disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

 

  • Trends in Autoimmune partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Autoimmune partnering agreement structure
  • Autoimmune partnering contract documents
  • Top Autoimmune deals by value
  • Most active Autoimmune dealmakers

                   

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

                          

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

 

The report includes coverage of the following autoimmune diseases:

 

Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison’s disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

 

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

 

The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.

 

Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

 

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

                              

Chapter 4 provides a review of the leading Autoimmune deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

                                                                       

Chapter 5 provides comprehensive access to Autoimmune deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2014. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2014.      

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Global Autoimmune Partnering 2014 to 2021 provides the reader with the following key benefits:

 

  • In-depth understanding of Autoimmune deal trends since 2014
  • Access Autoimmune deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Autoimmune partner companies
  • Comprehensive access to over 900 links to actual Autoimmune deals entered into by the world’s biopharma companies
  • Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Autoimmune opportunities
  • Uncover companies actively partnering Autoimmune opportunities

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Autoimmune dealmaking

 

2.1. Introduction

2.2. Autoimmune partnering over the years        

2.3. Autoimmune partnering by deal type

2.4. Autoimmune partnering by industry sector

2.5. Autoimmune partnering by stage of development

2.6. Autoimmune partnering by technology type

2.7. Autoimmune partnering by therapeutic indication

 

Chapter 3 –Financial deal terms for Autoimmune partnering

 

3.1. Introduction

3.2. Disclosed financials terms for Autoimmune partnering

3.3. Autoimmune partnering headline values

3.4. Autoimmune deal upfront payments

3.5. Autoimmune deal milestone payments

3.6. Autoimmune royalty rates

 

Chapter 4 – Leading Autoimmune deals and dealmakers

 

4.1. Introduction

4.2. Most active in Autoimmune partnering

4.3. List of most active dealmakers in Autoimmune        

4.4. Top Autoimmune deals by value

 

Chapter 5 – Autoimmune contract document directory

                                            

5.1. Introduction

5.2. Autoimmune partnering deals where contract document available

 

Chapter 6 – Autoimmune dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by Autoimmune therapeutic target

 

Appendices

 

Appendix 1 – Directory of Autoimmune deals by company A-Z since 2014

Appendix 2 – Directory of Autoimmune deals by deal type since 2014

Appendix 3 – Directory of Autoimmune deals by stage of development since 2014

Appendix 4 – Directory of Autoimmune deals by technology type since 2014

Further reading on dealmaking

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Autoimmune partnering since 2014

Figure 2: Autoimmune partnering by deal type since 2014

Figure 3: Autoimmune partnering by industry sector since 2014

Figure 4: Autoimmune partnering by stage of development since 2014

Figure 5: Autoimmune partnering by technology type since 2014

Figure 6: Autoimmune partnering by indication since 2014

Figure 7: Autoimmune deals with a headline value

Figure 8: Autoimmune deals with upfront payment values

Figure 9: Autoimmune deals with milestone payment

Figure 10: Autoimmune deals with royalty rates

Figure 11: Active Autoimmune dealmaking activity since 2014

Figure 12: Top Autoimmune deals by value since 2014

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3Derm Systems, 3M Drug Delivery Systems, 3SBio, 23andMe, Aavis Pharmaceuticals, Abarca, AB Biosciences, Abbott Laboratories, Abbvie, Ablynx, Abreos Biosciences, AbSci, Abzena, AC Bioscience, Accelerated Cure Project for MS, Accelis Pharma, Accord Healthcare, Aceso Life Science, Aclaris Therapeutics, Acorda Therapeutics, Acucela, Adacyte Therapeutics, AdAlta, Adare Pharma Solutions, Adherium, Adocia, Aduro BioTech, Adynxx, Aequus Pharmaceuticals, Aerial BioPharma, Aerpio Pharmaceuticals, Aesthetic Management Partners, Aevi Genomic Medicine, Affibody, AffyXell Therapeutics, Afimmune, AGC Biologics, AgeX Therapeutics, AIDS Clinical Trials Group, AiVita Biomedical, Akaal Pharma, Akebia Therapeutics, Akorn, Akouos, Akston Biosciences, Alana Healthcare, Alba Therapeutics, Alexion Pharmaceuticals, Alfasigma, Alivio Therapeutics, Alkermes, Allakos, Allegheny Technologies, Allegro Ophthalmics, Allen Institute for Brain Science, Allergan, Allergan (name changed from Actavis), Alliance for Lupus Research, Alma Bio Therapeutics, Almirall, Alnylam Pharmaceuticals, Alpha Cancer Technologies, Alpine Immune Sciences, Altair, AltaVoice, ALTuCELL, Alvine Pharmaceuticals, Alvit LCS Pharma, Alvotech, Alzheimer's Association, Amarex Clinical Research, Amarna Therapeutics, Ambiopharm, Ambry Genetics, Amegabiotech, American College of Chest Physicians, American Diabetes Association, American Lung Association, American National Multiple Sclerosis Society, American Skin Association, Amgen, AmorChem, AMPEL BioSolutions, Andromeda Biotech, AnGes MG, Angiocrine Bioscience, Anika Therapeutics, ANI Pharmaceuticals, Annette Funicello Research Fund for Neurological Diseases (AFRFND), Anokion, Anthem Bluecross, Anthera Pharmaceuticals, AntibioTx, Antidote, Apexigen, Aphios, Applied Biology, Applied BioMath, Applied Molecular Transport, Aptar Pharma, Aptuit, Aralez Pharmaceuticals, Aratana Therapeutics, Arch Biopartners, Arctic Vision, Arcutis Biotherapeutics, Arena Pharmaceuticals, argenx, Aristea Therapeutics, Ark Biosciences, Array Biopharma, Arrien Pharmaceuticals, Artisan Bio, Artizan Biosciences, Asana Medical, ASKA Pharmaceuticals, AskAt, Assembly Biosciences, Astellas Pharma, Asthma UK, Astion Pharma, AstraZeneca, Atara Biotherapeutics, Atnahs Pharma, Atopix, Atreca, Aurinia Pharmaceuticals, Auris Medical, Australasian Gastro Intestinal Research Foundation, Avacta, Avalere Health, Axela, AXIM Biotechnologies, Axsome Therapeutics, Azitra, Bachem, Back-A-Line, Basilea Pharmaceutica, Bausch & Lomb, Bausch Health Companies, Baxalta, Baxter International, Bayer, Baylor Health Care System, Baylor Research Institute, Bazelet, BC Children's Hospital, BCD Bioscience, BDD Pharma, Beijing Tide Pharmaceutical, BenevolentAI, Berg, Beta-O2, Beyond Type 1, BGI, BHR Pharma, Biametrics, Bigfoot Biomedical, Bill and Melinda Gates Foundation, Bina Technologies, Bio-Cancer Treatment International, Bio-Path, Bio-Rad Laboratories, Bio-Techne, Bio-Thera Solutions, biOasis Technologies, BioCad Holding, BioClinica, Biocon, Biofourmis, Biogen, Biohaven Pharmaceutical Holding, BiolineRX, Biolojic Design, Biomecite Diagnostics, Biomedical Catalyst Fund (UK), BioMed X Innovation Center, BiomX, Bionure, Bioprojet, BioRap Technologies, BioReliance, BioSense Global, BioStorage Technologies, BirchBioMed, BL&H, Blue Cross Blue Shield Association, BlueRock Therapeutics, Blue Shield of California, Boehringer Ingelheim, Boragen, Boston Pharmaceuticals, Boston University School of Medicine, Bpifrance, BrainStorm Cell Therapeutics, Breakthrough Health, Breckenbridge Pharmaceutical, Brickell Biotech, Bridge Biotherapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, British Lung Foundation, Broad Institute, Brown University, Buck Institute for Age Research, Cabaletta Bio, Cadila Pharmaceuticals, Caladrius Biosciences, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Calliditas Therapeutics, Calypso Biotech, Camargo Pharmaceutical Services, Cambridge Clinical Laboratories, Cambridge Enterprise, Camino Partnership, Cam Med, Can-Fite BioPharma, Canbex Therapeutics, Canigma, Cannassure Therapeutics, Cantargia, Cara Therapeutics, CareFirst BlueCross BlueShield, Casebia Therapeutics, Case Western Reserve University, Catalyst Pharmaceuticals, CEA-Leti, Cedars-Sinai Medical Center, Celdara Medical, Celgene, Celiac Disease Foundation, Celimmune, Cell Therapy Catapult, Celltrion, Celmatix, Celon Pharma, Cel Sci, Celsius Therapeutics, Central Institute for Experimental Animals, Centre for Drug Research and Development (CDRD), Centre Hospitalier Régional Universitaire (CHRU) de Lille, Centre National de la Recherche Scientifique, Centurion, Changchun High & New Technology Industries, CheckPoint Immunology, Chelexa Biosciences, Chiesi Farmaceutici, Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, Children's Hospital Boston, Chinese University of Hong Kong, Chong Kun Dang, Chronos Therapeutics, Chugai Pharmaceutical, CHU Sainte-Justine, Cicero Diagnostics, Cigna Healthcare, Cipher Pharmaceuticals, Cipla, Circassia, Citrine Medicine, Clal Biotech, Clarify Medical, Clearside Biomedical, Clene Nanomedicine, Cleveland Clinic, Clinigen, CMS Medical, Cochin Hospital, Coherus Biosciences, Columbia University, Columbia University Medical Center, Complix, Convelo Therapeutics, Cook Biotech, COPD Foundation, Corbin Therapeutics, Corbus Pharmaceuticals, CORD:USE, Cornell University, Corrona, CorTechs Labs, COUR Pharmaceutical, Covalent Data, CRISPR Therapeutics, Critical Path Institute (C-Path), Crohn's and Colitis Foundation of America, CR Pharma, CRS Bio, CrystalGenomics, CSL Behring, Cue Biopharma, Cumberland Pharmaceuticals, Curable, Curant Health, Cureveda, CyDex, Cynata Therapeutics, Cytocom, Cytori Therapeutics, Cyxone, Daewoong Pharmaceutical, Daiichi Sankyo, Dalton Pharma Services, Dartmouth College, DBV Technologies, Debiopharm, Debiotech, DecImmune Therapeutics, Defymed, Delphi Genetics, Denali Therapeutics, DendroCyte, Department of Defense, Dermavant Sciences, Dermira, DexCom, Diabeloop, Diagnostic International Distribution, Diamyd Medical, Diomics, Diplomat, Diurnal, Diversigen, Domainex, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Draper Laboratories, DreaMed Diabetes, DS Biopharma, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University, EA Pharma, Eddingpharm, EffRx, EGeen, Eisai, Eisai Inc, Eleven Biotherapeutics, Eli Lilly, Elite Pharmaceuticals, ElsaLys Biotech, EMD Serono, Emory University, EMS, Enable Biosciences, Encore Dermatology, Endo International, enGene, Engitix, Entera Health, Enteris Biopharma, Enterome Bioscience, Entos Pharmaceuticals, EOFlow, Epicore Biosystems, EPI Health, Epirus Biopharmaceuticals, Epivax, Equillium, Erasmus University Medical Center, Ethos Research & Development, Ethypharm, European Bioinformatics Institute, European Union, European Union Regional Development Fund, Everest Medicines, Evestra, Evidation Health, Evolve BioSystems, Evommune, EVOQ Therapeutics, Evotec, Ewopharma, Exagen Diagnostics, Exco InTouch, ExeGi Pharma, Exicure, ExScientia, EyePoint Pharmaceuticals, FairJourney Biologics, Fast Forward, Fate Therapeutics, Federal Ministry of Education and Research (BMBF), Federal Ministry of Health (Germany), Feinstein Institute for Medical Research, Ferring Pharmaceuticals, Fibrocor Therapeutics, Finch Therapeutics, Fission Labs LATAM, Flemish agency for Innovation by Science and Technology, Fluidigm, Food and Drug Administration (FDA), Foresee Pharmaceuticals, Forward Pharma, Fougera Pharmaceuticals, Foundation for Celiac Disease Outcome Measures, Foundation for Diabetes Research, Fred Hutchinson Cancer Research Center, French National Institute for Agricultural Research, Fresenius Kabi Pharmaceuticals, FSD Pharma, Fudan University, Fujifilm Diosynth Biotechnologies, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fundacion Progreso y Salud, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Galapagos, Galderma, Galecto, Gebro Pharma, Gedeon Richter, GE Healthcare, Genentech, Generex Biotechnology, Genetic Analysis, GeNeuro, Genexine, Genmab, Genomics, Genprex, Genten Therapeutics, Genzyme, Georgetown University, George Washington University, Georgia State University, Gilead Sciences, GI Reviewers, GlaxoSmithKline, Glenmark Pharmaceuticals, Glialogix, Global Centers for Therapeutic Innovation, Google, Gossamer Bio, Government of Australia, Graviton Bioscience, Green Park Collaborative, Grunenthal, Guangzhou Institute of Respiratory Disease, Guthy-Renker, GW Pharmaceuticals, Gynica, Hadasit Bioholdings, Hadasit Medical Research Services and Development, Halozyme Therapeutics, HanAll Pharmaceuticals, Hangzhou Zhongmei Huadong Pharmaceutical, Hanmi Pharmaceutical, Hannover Medical School, Haplogen, Happify Health, HAPPYneuron, Hapten Sciences, Harbour Biomed, Harmony Biosciences, Harvard Stem Cell Institute, Harvard University, Harvest Capital Strategies, Healthcare Royalty Partners, HealthPrize Technologies, Helius Medical Technologies, Helmholtz Zentrum Munchen, Hertie Foundation, Hesperos, Highland Therapeutics, Highmark Blue Shield, Highmark Health, Hikma Pharmaceuticals, Hob Diagnostics, Hoffmann La Roche, Hope Medicine, Horizon Pharma plc, Horizon Therapeutics, Hospital for Special Surgery, Hoth Therapeutics, Humanigen, Hyperion Therapeutics, I-mab, Iagnosis, iBio, IBM, Icahn School of Medicine at Mount Sinai, Ichnos Sciences, Ideal Life, Idera Pharmaceuticals, IDIS Pharma, IFM Therapeutics, ILTOO Pharma, ImaginAb, Imbio, Imcyse, IMIDomics, Immugenyx, ImmunArray, Immune Pharmaceuticals, Immune Therapeutics, ImmuNext, Immunic, ImmunogenX, Immunomic, Immunovia, ImmuPharma, Inception 5, Inception Sciences, Incyte, InDex Pharmaceuticals, Industrial Technology Research Institute, Inexia, Infinity Group, Inmagene Biopharmaceuticals, Innate Pharma, Innovate Biopharmaceuticals, Innovate UK, Innovation Pharmaceuticals, Innovative Genomics Initiative (IGI), Innovent Biologics, Inovalon, Inovio Pharmaceuticals, Inserm Transfert, Insmed Inc, Institute for Genome Statistics and Bioinformatics, Institute of Biophysics, Institute of Endocrinology, Metabolism, and Reproduction, Institute of Human Genetics, Institut Gustave Roussy, Instituto de Ciencias Farmaceuticas, Intarcia Therapeutics, Integral Molecular, International Progressive MS Alliance, International Society for Neurovascular Disease (ISNVD), Intralytix, Intrexon, Inventiva, Invion, Ionis Pharmaceuticals, IONTAS, Io Therapeutics, Ipsen, IQVIA, ISA Scientific, ISD Immunotech, iSense CGM, ISIS Innovation, Italian Multiple Sclerosis Society, Iterative Scopes, IXICO, Izana Bioscience, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Sciences, Janus Pharmaceuticals, Japan Tobacco, Jazz Pharmaceuticals, JHL Biotech, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Jubilant Pharma, Jubilant Radiopharma, Jubilant Therapeutics, Juno Therapeutics, Juntendo University, Juvenile Diabetes Research Foundation, JW Pharmaceutical, Kadimastem, Kaken Pharmaceutical, Kamada, Kanyos, Karolinska Institute, Karyopharm Therapeutics, KBI BioPharma, Keck Graduate Institute of Applied Life Sciences, Keck School of Medicine of USC, Keio Gijuku University, Kennedy Trust For Rheumatology Research, Kenneth Rainin Foundation (KRF), KineMed, King's College Hospital, Kiniksa Pharmaceuticals, Kissei Pharmaceutical, Kite Pharma, Klue, Knopp Biosciences, Kubota Vision, KYE Pharmaceuticals, Kyongbo Pharm, Kyowa Hakko Kirin, Kyverna Therapeutics, Lannett, Laurel Venture Capital, Lawson Health Research Institute, Lead Pharma, Legacy Biotechnologies, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Les Laboratoires Servier, Lexicon Pharmaceuticals, LifeArc, Ligand Pharmaceuticals, Lipidor, Lipid Therapeutics, LMU University Hospital Munich, Lonza, Lubeck Institute of Experimental Dermatology, Lumicera Health Services, Luminary Therapeutics, Lumir Lab, Lung Biotechnology, Lupin, Lupin Limited, Lupus Foundation of America (LFA), Lupus Research Alliance, Lupus Research Institute, Lupus Therapeutics, Lurie Children's Hospital of Chicago, Lyfebulb, MaaT Pharma, mAbXience, Macrogenics, MainPointe, Mallinckrodt Pharmaceuticals, MannKind Biopharmaceuticals, Mapi Pharma, Mariel Therapeutics, Marinomed Biotechnologie, Maryland Stem Cell Research Fund, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Maxhealth Medicine, Mayne Pharma, Mayo Clinic, MC2 Therapeutics, MC10, McGill University, McMaster University, MDNA Life Sciences, Med-Aesthetic Solutions, Medac, Medexus Pharmaceuticals, Medgenics, Medical College of Wisconsin, Medical International Research, Medical Research Council, Medical University of Graz, Medical University of South Carolina, Medical University of Vienna, Medical University South Carolina, Medicines Discovery Catapult, Medidata Solutions, MediGene, Medimetriks, MedImmune, Mediq, MELA Sciences, Menarini Asia-Pacific, Merck and Co, Merck Serono, Merck Sharpe & Dohme, Mereo BioPharma, Merus, Merz, Mesoblast, Metrion Biosciences, Michepro, Microbio Shanghai, Microbiotica, MicroConstants, Microdrop, Midatech, Miravo Healthcare, MiTest Health, Mitsubishi Tanabe Pharma, Modern Biosciences, Molecular Stethoscope, Molnlycke Health Care, Momenta Pharmaceuticals, Monash University, Morphic Therapeutic, MorphoSys, Mor Research Applications, Mount Sinai Medical Center, Mount Tam Biotechnologies, Mundipharma, Myelin Repair Foundation (MRF), Mylan Laboratories, Mylan Pharmaceuticals, Myovant Sciences, Myriad Genetics, NantWorks, National Center for Advancing Translational Sciences (NCATS), National Eczema Association, National Health Service, National Heart, Lung and Blood Institute, National Institute for Health Research (NIHR), National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Kidney Foundation, National Organization for Rare Disorders, National Psoriasis Foundation, National Science Foundation, Naval Medical Research Center, Navidea Biopharmaceuticals, Navitas, ndd Medical Technologies, Nektar Therapeutics, Neostell, Neos Therapeutics, Neoteryx, Neovacs, Neovii Pharmaceuticals, Nestle Health Science, NeuClone, New Amsterdam Sciences, NewSurg, New York University, New York University School of Medicine, Nextera, Nimbus Therapeutics, Ningbo Tai Kang Medical Technology, Nitto BioPharma, Nitto Denko, NLS Pharmaceutics, Nobelpharma, Nodality, Nogra Pharma, Nonin Medical, Nordic Pharma Group, Norgine, North Carolina State University, Northern Biologics, Northwestern University, North Zealand University Hospital, Nortis, Nostrum Pharmaceuticals, NovaMedica, Novan, Novare Pharmaceuticals, Novartis, NovaSAID, Novici Biotech, NovImmune, Novo Nordisk, Novoron Bioscience, Novozymes, Novozymes Biopharma, Nuevolution, Numab, numares, NuMedii, Nutra Pharma, Nuvilex, NYU Langone Medical Center, ObsEva, Ocata Therapeutics, Ocumension Therapeutics, Oklahoma Medical Research Foundation, Oneness Biotech, Ono Pharmaceutical, Optimeos Life Sciences, Or-Genix Therapeutics, Orca Pharmaceuticals, Orexia Therapeutics, Orgenesis, Orion, OSE Immunotherapeutics, Oslo University Hospital, Osmotica Pharmaceuticals, Ospedale San Raffaele, Otifex Therapeutics, Otsuka, OWC Pharmaceutical Research, Owlstone Medical, OxyPharma, PACA Inovation, Padlock Therapeutics, Pais Vasco University, Paladin Labs, Palisade Bio, Palobiofarma, Panaxia, Pandion Therapeutics, Panorama Research, Panther Biotechnology, Paragon Bioservices, ParcelShield, Parexel, Parexel Biotech, Parion Sciences, Particle Sciences, Parvus Therapeutics, Patara Pharma, PathoQuest, Patient-Centered Outcomes Research Institute (PCORI),, PatientsLikeMe, PEAR Therapeutics, Pediatric Dermatology Research Alliance, Pendopharm, Perelman School of Medicine, Perrigo, Pfizer, Pfizer Japan, Pharmapark, Pharmaxis, Pharmstandard, Philips, PhotoMedex, PhytoTech Medical, PicnicHealth, PlantEXT, Pluristem Therapeutics, Polpharma, Pooyesh Darou, Popit, Portage Biotech, Portal Instruments, PPD, Precision Image Analysis, PredictImmune, Prestium Pharma, Prime Therapeutics, Principia Biopharma, ProciseDx, Procyon Technologies, Progentec Diagnostics, Promethera Biosciences, Prometheus Laboratories, Promius Pharma, Propagenix, Propeller Health, ProQR Therapeutics, Protagen, Protagonist Therapeutics, Protalix BioTherapeutics, Protein Sciences, Protxx, Provention Bio, Provider Network of America, Proximagen Group, Pulmagen Therapeutics, Pulmatrix, Pulmonary Fibrosis Foundation (PFF), Purdue Pharma, PvP Biologics, Qiagen, Qualcomm, Qualyst Transporter Solutions, Qu Biologics, Queensland Institute of Medical Research (QIMR), Quell Therapeutics, Quotient Clinical, R-NAV, R-Tech Ueno, Rabin Medical Center (Beilinson Hospital), Radboud University Nijmegen Medical Centre, Rafa Pharmaceuticals, Raffles PharmaTech, Ranbaxy Laboratories, RedHill Biopharma, Redx Pharma, Reedy Creek Investments, Regen BioPharma, Regeneron Genetics Center, Regentys, REGiMMUNE, Regis Technologies, Regulus Therapeutics, Replicel Life Sciences, ReproCell, ResearchMatch, Reset Therapeutics, Respirent Pharmaceuticals, Revive Therapeutics, Revon Systems, ReWalk Robotics, Rheumatology Research Foundation, Rheumco, Rigel Pharmaceuticals, Rochal Industries, Roche, Rockefeller University, Rogne Bioscience, Roivant Sciences, Rosetta Genomics, Royal Philips Electronics, Royalty Pharma, RXi Pharmaceuticals, SAB Biotherapeutics, Sailing Sclerosis Foundation, Salix Pharmaceuticals, Samsung Bioepis, Samsung Biologics, Samumed, Sandoz, Sanford Health, Sanguine, Sanofi, San Raffaele Hospital, San Raffaele Telethon Institute for Gene Therapy, SarcoMed USA, SATT Lutech, Schneider Children's Medical Center, Scholar Rock, Schrodinger, SciCann Therapeutics, Science 37, Scienion, ScinoPharm Taiwan, Scipher Medicine, Scleroderma Research Foundation, Scripps Research Institute, Seattle Children's Hospital, Seattle Childrens Research Institute, Second Genome, Seelos Therapeutics, Selecta Biosciences, Selexis, Semma Therapeutics, Sengenics, Seres Therapeutics, Sernova, Serum Institute of India, SFC Fluidics, Shenzhen Hybio Pharma, Shepherd Center, Shire Laboratories, Shire Pharmaceuticals, Siemens Healthineers, Sigilon Therapeutics, SignaBlok, Signum Biosciences, Silence Therapeutics, Silo Pharma, Simbec Research, Sitryx, SK Biopharmaceuticals, SkyePharma, Skyhawk Therapeutics, SomaLogic, Sonoma Pharmaceuticals, Sonora Quest Laboratories, Sorrento Therapeutics, Sosei Heptares, Sourcia, Spesana, Spring Bank Pharmaceuticals, SQI Diagnostics, SRI International, St. Jude Children's Research Hospital, STADA Arzneimittel, Standigm, Stanford University, Stellar Biotechnologies, Stiefel Laboratories, Stony Brook University, Strainprint Technologies, Structural Genomics Consortium, Stryker, Summa Health System, SunGen, Sunovion Pharmaceuticals, Sun Pharmaceutical, Symbiotix Biotherapies, Synlogic, Systems Oncology, Takeda Pharmaceutical, Tanner Pharmaceuticals, TARGET PharmaSolutions, Tasly Pharmaceuticals, Tavotek Biotherapeutics, Technology Strategy Board (UK), Tel Aviv Sourasky Medical Center, Tetragenetics, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, Texas A&M University, TG Therapeutics, The Alfred Hospital, The Alpha-1 Project, The Cell and Gene Therapy Unit, The Consortium of Rheumatology Researchers of North America, The Crohn's and Colitis Foundation of Canada, The HUB Foundation, The Innovation Fund, The Multiple Sclerosis Association of America, The Myositis Association, Theradiag, Theravance, The Vancouver Island Health Authority, ThioLogics, Three Lakes Foundation, Tianhe Stem Cell Biotechnologies, Tidepool, TiGenix, Tillotts Pharma, Tissium, Tiziana Life Sciences, T Med, Topas Therapeutics, Torii Pharmaceutical, toSense, Tow Foundation, Traffick Therapeutics, TransBio, Transparency Life Sciences, Trialbee, Trizell, True Diagnostics, True North Therapeutics, Tsinghua University, Tufts Medical Center, twoXAR, TxCell, UCB, UGA Biopharma, UNION Therapeutics, United Therapeutics, University College Cork, University of Adelaide, University of Alberta, University of Birmingham, University of Bonn, University of British Columbia, University of Calgary, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Chicago, University of Cincinnati, University of Colorado, University of Colorado Denver, University of Connecticut, University of Houston, University of Illinois, University of Manitoba, University of Maryland, University of Maryland Baltimore, University of Maryland Ventures, University of Massachusetts, University of Massachusetts, Amherst, University of Michigan, University of Minnesota, University of North Carolina, University of North Texas Health Science Center, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rochester Medical Center, University of Sheffield, University of Sherbrooke, University of South Australia, University of South Carolina, University of South Florida, University of Technology Sydney, University of Texas at El Paso, University of Texas Southwestern Medical Center, University of Utah, University of Virginia, University of Washington, University of Windsor, University of Wisconsin-Madison, University of Zurich, University Pierre Marie Curie, Upsher-Smith, Utrecht University, Vaccinex, Valeant Pharmaceuticals, Vanderbilt University, Vasomune Therapeutics, Vcell Healthcare, V ClinBio, Vectura, Vedanta Biosciences, Veracyte, Verily, Versant Ventures, Vertex Pharmaceuticals, ViaCyte, Victoria University, Viela Bio, Vifor-Fresenius Medical Care Renal Pharma Ltd, Vinnova, Virginia Catalyst, Virginia Commonwealth University, Vital Connect, Vital Therapies, Vitesse Biologics, Vium, VolitionRX, Voyager Therapeutics, Weill Cornell Medical College, Wellcome Trust Sanger Institute, WellDyne, Wellness Center USA, White Rock Capital Partners, W L Gore, WorldCare Clinical, Worldwide Clinical Trials, Wuhan Kindstar Diagnostics, WuXi Biologics, Wyss Institute, X-Rx, XBiotech, Xbrane Bioscience, XL-Protein, Xoma, XTL Biopharmaceuticals, Xycrobe Therapeutics, Yahoo Health, Yale School of Medicine, Yale University, Yangtze River Pharmaceutical Group, Yeda Research and Development Company, Yissum Research Development, YL Biologics, Yoshindo, ZAI Laboratory, ZappRx, Zenoaq, Zenyaku Kogyo, Ziarco Pharma, Ziopharm Oncology, Zylo Therapeutics, Zymeworks, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.